[Clinical aspects of a new, very low dose combination contraceptive].
In a multicentre trial in Yugoslavia 150 fertile women were treated during 2541 menstrual cycles with Ovoresta M, a new low-dosed combined oral contraceptive pill. Each tablet contains 0.75 mg lynestrenol and 0.0375 mg ethinyloestradiol. Evaluation of the results shows that there were no pregnancies. Irregular bleedings occurred in 8.1% of all cycles. The side effects recorded were mainly due to the fact that for 140 of the 150 participants this was the first oral contraceptive they ever used. 2 women dropped out for relevant reasons (irregular bleedings). Because of the low dosage of active ingredients the authors consider Ovoresta M a welcome supplement to the existing oral contraceptives.
D000293:Adolescent; D000328:Adult; D003276:Contraceptives, Oral / Q000494:pharmacology*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology*; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000494:pharmacology*; D008598:Menstruation
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol; D008234:Lynestrenol
Klinische Aspekte eines neuen, sehr niedrig dosierten Kontrazeptivums vom Kombinationstyp.